AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7001230 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) plus radiotherapy
Number of subjects: 467
Study 7001230 — intervention group
Group type: EXPERIMENTAL
Intervention: Semustine (MeCCNU) plus radiotherapy
Number of subjects: 467
Study 30844795 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol spraying + Carbon Dioxide insufflation (n = 153)
Number of subjects: 611
Study 30844795 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol spraying + Air insufflation (n = 156)
Number of subjects: 611
Study 30844795 — intervention group
Group type: COMPARATOR
Intervention: Carbon Dioxide insufflation (n = 153)
Number of subjects: 611
Study 30844795 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation (n = 149)
Number of subjects: 611
Study 30844795 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol spraying
Number of subjects: 611
Study 30844795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide insufflation
Number of subjects: 611
Study 29502468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CIN) single dose (1, 2, 4 tablets)
Number of subjects: 12
Study 29502468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CIN) multiple dose (1 mg three times a day)
Number of subjects: 12
Study 29502468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CIN) single and multiple doses
Number of subjects: 12
Study 27771748 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral d-amphetamine
Number of subjects: 84
Study 27771748 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral d-amphetamine (G/A + G/G genotypes)
Number of subjects: 84
Study 27771748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26482675 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of electrographic seizures (ESG)
Number of subjects: 69
Study 26482675 — intervention group
Group type: COMPARATOR
Intervention: Treatment of clinical seizures (CSG)
Number of subjects: 69
Study 26482675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohort (both ESG and CSG)
Number of subjects: 69
Study 23371976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) meals
Number of subjects: 11
Study 23371976 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) meals
Number of subjects: 11
Study 23371976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 11
Study 21330401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 121
Study 21330401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 19524862 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive anemia care in CKD clinic
Number of subjects: 79
Study 19524862 — intervention group
Group type: COMPARATOR
Intervention: Baseline QOL in CKD patients
Number of subjects: 79
Study 18181515 — intervention group
Group type: EXPERIMENTAL
Intervention: S100b levels at the end of bypass (mean 0.30 microg/L, SD +/- 0.33, range 0.00 to 1.57)
Number of subjects: 55
Study 18181515 — intervention group
Group type: EXPERIMENTAL
Intervention: S100b levels at the end of bypass
Number of subjects: 55
Study 18181515 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological battery of 9 tests administered 6-8 weeks post-operatively
Number of subjects: 55
Study 18181515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microemboli counts recorded by transcranial Doppler monitor
Number of subjects: 55
Study 15055569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 571
Study 15497271 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional Program 1
Number of subjects: 60
Study 15497271 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional Program 2
Number of subjects: 60
Study 15497271 — intervention group
Group type: COMPARATOR
Intervention: Both Instructional Programs
Number of subjects: 60
Study 9863091 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianfei Pill (JFP)
Number of subjects: 56
Study 9863091 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 7934346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (2500 IU daily)
Number of subjects: 200
Study 7934346 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg) and dipyridamole (100 mg 8 hourly)
Number of subjects: 200
Study 2888421 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sufentanil
Number of subjects: 30
Study 2888421 — intervention group
Group type: COMPARATOR
Intervention: 5 mg morphine
Number of subjects: 30
Study 29754275 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol paste (ZOE)
Number of subjects: 32
Study 29754275 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodoform paste (Guedes‐Pinto paste)
Number of subjects: 32
Study 29754275 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste thickened with zinc oxide
Number of subjects: 32
Study 29754275 — intervention group
Group type: COMPARATOR
Intervention: No filling paste (control)
Number of subjects: 32
Study 28394705 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluad™ vaccination (Novartis, Italy) with a 5-visit schedule (day 0, 1/3, 7, 21, 70)
Number of subjects: 234
Study 26022103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT/MED)
Number of subjects: 95
Study 26022103 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU/MED)
Number of subjects: 95
Study 22240615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 140
Study 22240615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg kg(‐1)
Number of subjects: 140
Study 22240615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1)
Number of subjects: 140
Study 22240615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg kg(‐1)
Number of subjects: 140
Study 21071270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m²), gemcitabine (1000 mg/m²), and oxaliplatin (100 mg/m²) every 2 weeks for 12 cycles
Number of subjects: 30
Study 17349883 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 3445
Study 17349883 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 3445
Study 16358378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight-heparin (LMWH)
Number of subjects: 114
Study 16358378 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH)
Number of subjects: 114
Study 11942873 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG) monitoring
Number of subjects: 120
Study 11942873 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria without nerve stimulator
Number of subjects: 120
Study 9616240 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid in situ during fluoroscopy
Number of subjects: 0
Study 9616240 — intervention group
Group type: COMPARATOR
Intervention: Grid removed for fluoroscopy
Number of subjects: 0
Study 7815675 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium diglycinate (100 mg dose)
Number of subjects: 12
Study 7815675 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (MgO)
Number of subjects: 12
Study 2698517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Delagil therapy
Number of subjects: 16
Study 2698517 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment
Number of subjects: 16
Study 970386 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine acid phosphate at a dose of 76 mug/kg
Number of subjects: 20
Study 970386 — intervention group
Group type: COMPARATOR
Intervention: Histamine acid phosphate at a dose of 3.2 mg
Number of subjects: 20
Study 970386 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine acid phosphate at various doses (40, 70, 76, 80 mug/kg and 3.2 mg)
Number of subjects: 20
Study 30630341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (bolus followed by 2-hour infusion)
Number of subjects: 50
Study 30630341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bolus followed by 2-hour infusion)
Number of subjects: 50
Study 30630341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor and Ticagrelor (180-mg loading dose administered as crushed tablets)
Number of subjects: 50
Study 30322081 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cow-protein (WC)
Number of subjects: 30
Study 30322081 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole goat-protein (WG)
Number of subjects: 30
Study 30322081 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially-hydrolysed whey cow-protein (HC)
Number of subjects: 30
Study 26839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 144 mg/day
Number of subjects: 48
Study 26839321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24876197 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundle to promote maternal breast milk (MBM) in the East of England (EoE)
Number of subjects: 144
Study 22687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (TR-701) 200, 300, or 400 mg orally once daily for 5 to 7 days
Number of subjects: 196
Study 22687509 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (Zyvox)
Number of subjects: 196
Study 20128580 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional ultrasound (Infiniti Vision System; Alcon Laboratories, Fort Worth, TX)
Number of subjects: 360
Study 20128580 — intervention group
Group type: COMPARATOR
Intervention: Microburst with longitudinal ultrasound (Infiniti)
Number of subjects: 360
Study 20128580 — intervention group
Group type: COMPARATOR
Intervention: Microburst with longitudinal ultrasound (Legacy Everest, Alcon Laboratories)
Number of subjects: 360
Study 17287635 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg once daily)
Number of subjects: 380
Study 17287635 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 380
Study 17287635 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 380
Study 16249727 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser preparation of retrograde cavities
Number of subjects: 60
Study 16249727 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic device preparation of retrograde cavities
Number of subjects: 60
Study 12126250 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema 2 mg/100 ml, administered twice daily (b.i.d.)
Number of subjects: 149
Study 12126250 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema twice weekly
Number of subjects: 149
Study 12126250 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 149
Study 10216904 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 micrograms kg-1 day-1
Number of subjects: 46
Study 10216904 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 micrograms kg-1 day-1
Number of subjects: 46
Study 10216904 — intervention group
Group type: COMPARATOR
Intervention: No PBSC collection
Number of subjects: 46
Study 7618970 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination (norfloxacin, colistin, amphotericin)
Number of subjects: 102
Study 7618970 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 102
Study 7618970 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination
Number of subjects: 102
Study 2487573 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA-prednisolone regimen
Number of subjects: 137
Study 2487573 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-prednisolone regimen
Number of subjects: 137
Study 30522020 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of high‐top boots and custom made rigid contoured carbon fibre foot orthoses
Number of subjects: 15
Study 28881249 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT-guided management
Number of subjects: 0
Study 28881249 — intervention group
Group type: EXPERIMENTAL
Intervention: Broader NHS and PSS perspective of PET-CT management
Number of subjects: 0
Study 28881249 — intervention group
Group type: COMPARATOR
Intervention: Standard care (planned neck dissection)
Number of subjects: 0
Study 26718510 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN XT
Number of subjects: 560
Study 26718510 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN
Number of subjects: 560
Study 22820819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 830-1064 nm LASER (radiating dose: 250 J cm‐2 delivered to the skin overlying the course of the median nerve at the wrist for 100 s at 25 W)
Number of subjects: 20
Study 22820819 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) (100 Hz, 30 minutes; rectangular waves; 80 ms width, intensity below muscle contraction)
Number of subjects: 20
Study 20661545 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 28
Study 20661545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19619920 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 high-flux dialyzers in parallel for 4 hours
Number of subjects: 18
Study 17612056 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential omega-3 and omega-6 fatty acids
Number of subjects: 0
Study 17612056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 15598677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric high monounsaturated fat diet alone
Number of subjects: 33
Study 15598677 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (EX)
Number of subjects: 33
Study 15598677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (D+E)
Number of subjects: 33
Study 15598677 — intervention group
Group type: COMPARATOR
Intervention: Control (D intervention)
Number of subjects: 33
Study 12433226 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit display (GD) symbology
Number of subjects: 9
Study 12433226 — intervention group
Group type: COMPARATOR
Intervention: Conventional inside-out HUD symbology
Number of subjects: 9
Study 12433226 — intervention group
Group type: COMPARATOR
Intervention: Outside-in display symbology
Number of subjects: 9
Study 12433226 — intervention group
Group type: EXPERIMENTAL
Intervention: Front view orientation
Number of subjects: 9
Study 12433226 — intervention group
Group type: COMPARATOR
Intervention: Side view orientation
Number of subjects: 9
Study 9810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame Street Fresh Apple Splash bubble bath
Number of subjects: 0
Study 9810021 — intervention group
Group type: COMPARATOR
Intervention: Nine children's liquid bubble bath solutions
Number of subjects: 0
Study 7926528 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current electrocoagulation
Number of subjects: 100
Study 7926528 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocoagulation
Number of subjects: 100
Study 2556807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised nedocromil sodium 0.5 mg/ml
Number of subjects: 10
Study 2556807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised nedocromil sodium 5 mg/ml
Number of subjects: 10
Study 2556807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised nedocromil sodium 10 mg/ml
Number of subjects: 10
Study 2556807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised nedocromil sodium 20 mg/ml
Number of subjects: 10
Study 2556807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 2556807 — intervention group
Group type: COMPARATOR
Intervention: Control run (no treatment)
Number of subjects: 10
Study 1151647 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil‐in‐water emulsion (500 mg)
Number of subjects: 5
Study 1151647 — intervention group
Group type: COMPARATOR
Intervention: Aqueous suspension (500 mg)
Number of subjects: 5
Study 1151647 — intervention group
Group type: COMPARATOR
Intervention: Tablet A (500 mg)
Number of subjects: 5
Study 1151647 — intervention group
Group type: COMPARATOR
Intervention: Tablet B (500 mg)
Number of subjects: 5
Study 31289987 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention (12 hours)
Number of subjects: 32
Study 31289987 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual educational curriculum)
Number of subjects: 32
Study 28640061 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing bouts every 30 min during 9-h sitting (STAND)
Number of subjects: 14
Study 28640061 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min moderate-intensity walking bout followed by 8.5 h of sitting (MVPA)
Number of subjects: 14
Study 28640061 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min moderate-intensity walking bout followed by 15-min standing bouts every 30 min during 8.5 h of sitting (MVPA + STAND)
Number of subjects: 14
Study 25675335 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate FRT therapy
Number of subjects: 20
Study 25675335 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate VFE therapy
Number of subjects: 20
Study 25675335 — intervention group
Group type: COMPARATOR
Intervention: Delayed FRT therapy
Number of subjects: 20
Study 25675335 — intervention group
Group type: COMPARATOR
Intervention: Delayed VFE therapy
Number of subjects: 20
Study 25675335 — intervention group
Group type: EXPERIMENTAL
Intervention: FRT therapy
Number of subjects: 20
Study 25675335 — intervention group
Group type: EXPERIMENTAL
Intervention: VFE therapy
Number of subjects: 20
Study 24776332 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple strategy
Number of subjects: 69
Study 24776332 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex strategy
Number of subjects: 69
Study 24776332 — intervention group
Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 69
Study 21670776 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative group: 2g amoxycillin capsules and 1g metronidazole tablets one hour before extraction
Number of subjects: 84
Study 21670776 — intervention group
Group type: COMPARATOR
Intervention: Postoperative group: 500mg amoxycillin capsules thrice daily and 400mg metronidazole tablets thrice daily for five days
Number of subjects: 84
Study 19308796 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based computerized patient education
Number of subjects: 311
Study 19308796 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional patient education
Number of subjects: 311
Study 19308796 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 311
Study 16981032 — intervention group
Group type: EXPERIMENTAL
Intervention: Puncture in the left hypochondrium (Group LH)
Number of subjects: 62
Study 16981032 — intervention group
Group type: COMPARATOR
Intervention: Puncture in the abdominal midline (Group ML)
Number of subjects: 62
Study 14750201 — intervention group
Group type: EXPERIMENTAL
Intervention: Kan Jang (adjuvant treatment)
Number of subjects: 130
Study 14750201 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunal (adjuvant treatment)
Number of subjects: 130
Study 14750201 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 130
Study 11384642 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized E(2) administered by the vaginal route
Number of subjects: 0
Study 11384642 — intervention group
Group type: COMPARATOR
Intervention: Micronized E(2) administered by the oral route
Number of subjects: 0
Study 11384642 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 0
Study 11384642 — intervention group
Group type: COMPARATOR
Intervention: Exogenous E(2) by the vaginal route
Number of subjects: 0
Study 11384642 — intervention group
Group type: COMPARATOR
Intervention: Endogenous E(2) produced by the ovaries
Number of subjects: 0
Study 9246881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 48
Study 9246881 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 48
Study 8487324 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (150 U/kg)
Number of subjects: 153
Study 2961290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg (F group; n = 142)
Number of subjects: 286
Study 2961290 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nalbuphine 300 micrograms/kg (LN group; n = 103)
Number of subjects: 286
Study 2961290 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nalbuphine 500 micrograms/kg (HN group; n = 41)
Number of subjects: 286
Study 29194177 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive micro‐prompting device
Number of subjects: 24
Study 29194177 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation
Number of subjects: 24
Study 27018610 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion Meditation (CM)
Number of subjects: 0
Study 27018610 — intervention group
Group type: COMPARATOR
Intervention: Placebo oxytocin
Number of subjects: 0
Study 27018610 — intervention group
Group type: COMPARATOR
Intervention: Familiarity intervention
Number of subjects: 0
Study 25159356 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM 30 µg
Number of subjects: 100
Study 25159356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25159356 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM 20 µg
Number of subjects: 100
Study 23816571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhGH (25 μg/kg/day)
Number of subjects: 111
Study 23816571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose rhGH (50 μg/kg/day)
Number of subjects: 111
Study 23816571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhGH (100 μg/kg/day)
Number of subjects: 111
Study 23816571 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rhGH
Number of subjects: 111
Study 20718901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 μg/kg, single dose)
Number of subjects: 80
Study 20718901 — intervention group
Group type: COMPARATOR
Intervention: Topical malathion lotion (0.5%, single application)
Number of subjects: 80
Study 18559234 — intervention group
Group type: EXPERIMENTAL
Intervention: Mahuang Zhisou Capsule (MHZSC)
Number of subjects: 240